How has been the historical performance of Aristo Bio-Tech?

Answer:The historical performance of Aristo Bio-Tech shows a consistent growth trajectory in net sales and profitability over the past five years. Breakdown: Aristo Bio-Tech's net sales have increased significantly from INR 165.76 crore in March 2022 to INR 318.09 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar pattern, rising from INR 167.22 crore in March 2021 to INR 318.09 crore in March 2025. However, raw material costs have also escalated, reaching INR 295.60 crore in March 2025, which has impacted the operating profit margin, which decreased from 4.0% in March 2023 to 2.91% in March 2025. Despite this, the operating profit (PBDIT) has shown improvement, growing from INR 4.36 crore in March 2021 to INR 9.72 crore in March 2025. Profit before tax has also increased, reaching INR 5.47 crore in March 2025, while profit after tax rose to INR 4.06 crore in the same period. The company's total assets have expanded from INR 77.00 crore in March 2022 to INR 140.62 crore in March 2025, indicating robust growth in its financial position. Total liabilities have also increased, but the shareholder's funds have grown significantly, reflecting a strengthening equity base. Cash flow from operating activities improved to INR 10.00 crore in March 2025, compared to INR -2.00 crore in March 2023, demonstrating better cash generation capabilities. Overall, Aristo Bio-Tech has shown a positive trend in sales and profitability, despite rising costs and liabilities.